Literature DB >> 25001848

MHC class I and II deficiencies.

Suheir Hanna1, Amos Etzioni2.   

Abstract

Deficiencies of MHC complex class I or II are rare primary immunodeficiencies, both of which are inherited in an autosomal recessive pattern. MHC class II deficiency is a prototype of a disease of gene regulation. Defects in transacting regulatory factors required for expression of MHC class II genes, rather than the genes themselves, are responsible for the disease phenotype. The affected genes are known to encode 4 distinct regulatory factors controlling transcription of MHC class II genes. These transacting factors are the class II transactivator and 3 subunits of regulatory factor X (RFX): RFX containing ankyrin repeats (RFXANK), the fifth member of the RFX family (RFX5), and RFX-associated protein (RFXAP). Mutations in one of each define 4 distinct complementation groups termed A, B, C, and D, respectively. MHC class I deficiency is extremely rare and has been reported in less than 30 patients worldwide. Here we review the clinical, genetic, and molecular features that characterize these primary immunodeficiencies and discuss therapy options. Beyond the description of MHC class I and II deficiencies, their discovery has fascinated scientists and clinicians because of their ability to reveal the molecular basis of MCH regulation.
Copyright © 2014 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.

Entities:  

Keywords:  MHC class I and II; class II transactivator; immunodeficiency; regulatory factor X; tapasin; transporter associated with antigen processing I and II

Mesh:

Substances:

Year:  2014        PMID: 25001848     DOI: 10.1016/j.jaci.2014.06.001

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  37 in total

1.  Novel Mutation in the Class II Transactivator Associated with Immunodeficiency and Autoimmunity.

Authors:  Aisha Ahmed; Walter Reith; Jennifer M Puck; Laurence E Cheng
Journal:  J Clin Immunol       Date:  2015-08-14       Impact factor: 8.317

2.  Dominant-negative IKZF1 mutations cause a T, B, and myeloid cell combined immunodeficiency.

Authors:  David Boutboul; Hye Sun Kuehn; Zoé Van de Wyngaert; Julie E Niemela; Isabelle Callebaut; Jennifer Stoddard; Christelle Lenoir; Vincent Barlogis; Catherine Farnarier; Frédéric Vely; Nao Yoshida; Seiji Kojima; Hirokazu Kanegane; Akihiro Hoshino; Fabian Hauck; Ludovic Lhermitte; Vahid Asnafi; Philip Roehrs; Shaoying Chen; James W Verbsky; Katherine R Calvo; Ammar Husami; Kejian Zhang; Joseph Roberts; David Amrol; John Sleaseman; Amy P Hsu; Steven M Holland; Rebecca Marsh; Alain Fischer; Thomas A Fleisher; Capucine Picard; Sylvain Latour; Sergio D Rosenzweig
Journal:  J Clin Invest       Date:  2018-06-11       Impact factor: 14.808

Review 3.  Human inborn errors of immunity to herpes viruses.

Authors:  Emmanuelle Jouanguy; Vivien Béziat; Trine H Mogensen; Jean-Laurent Casanova; Stuart G Tangye; Shen-Ying Zhang
Journal:  Curr Opin Immunol       Date:  2020-01-31       Impact factor: 7.486

4.  IFN-γ induces the upregulation of RFXAP via inhibition of miR-212-3p in pancreatic cancer cells: A novel mechanism for IFN-γ response.

Authors:  Guoping Ding; Liangjing Zhou; Tao Shen; Liping Cao
Journal:  Oncol Lett       Date:  2018-01-12       Impact factor: 2.967

Review 5.  Human genetic dissection of papillomavirus-driven diseases: new insight into their pathogenesis.

Authors:  Vivien Béziat
Journal:  Hum Genet       Date:  2020-05-20       Impact factor: 4.132

6.  Gain of Function Mutations of PIK3CD as a Cause of Primary Sclerosing Cholangitis.

Authors:  Heather N Hartman; Julie Niemela; Mary K Hintermeyer; Mary Garofalo; Jennifer Stoddard; James W Verbsky; Sergio D Rosenzweig; John M Routes
Journal:  J Clin Immunol       Date:  2014-10-29       Impact factor: 8.317

7.  Rebalancing Protein Homeostasis Enhances Tumor Antigen Presentation.

Authors:  Alex M Jaeger; Lauren Stopfer; Sunmin Lee; Giorgio Gaglia; Demi Sandel; Sandro Santagata; Nancy U Lin; Jane B Trepel; Forest White; Tyler Jacks; Susan Lindquist; Luke Whitesell
Journal:  Clin Cancer Res       Date:  2019-06-18       Impact factor: 12.531

8.  A human PSMB11 variant affects thymoproteasome processing and CD8+ T cell production.

Authors:  Izumi Ohigashi; Yuki Ohte; Kazuya Setoh; Hiroshi Nakase; Akiko Maekawa; Hiroshi Kiyonari; Yoko Hamazaki; Miho Sekai; Tetsuo Sudo; Yasuharu Tabara; Hiromi Sawai; Yosuke Omae; Rika Yuliwulandari; Yasuhito Tanaka; Masashi Mizokami; Hiroshi Inoue; Masanori Kasahara; Nagahiro Minato; Katsushi Tokunaga; Keiji Tanaka; Fumihiko Matsuda; Shigeo Murata; Yousuke Takahama
Journal:  JCI Insight       Date:  2017-05-18

9.  MHC II deficient infant identified by newborn screening program for SCID.

Authors:  Nufar Marcus; Tali Stauber; Atar Lev; Amos J Simon; Jerry Stein; Arnon Broides; Ido Somekh; Shlomo Almashanu; Raz Somech
Journal:  Immunol Res       Date:  2018-08       Impact factor: 2.829

10.  Phenome-wide association study maps new diseases to the human major histocompatibility complex region.

Authors:  Jixia Liu; Zhan Ye; John G Mayer; Brian A Hoch; Clayton Green; Loren Rolak; Christopher Cold; Seik-Soon Khor; Xiuwen Zheng; Taku Miyagawa; Katsushi Tokunaga; Murray H Brilliant; Scott J Hebbring
Journal:  J Med Genet       Date:  2016-06-10       Impact factor: 6.318

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.